Oxford Biomedica’s (OXB) “Buy” Rating Reaffirmed at Jefferies Financial Group

Oxford Biomedica (LON:OXB)‘s stock had its “buy” rating restated by Jefferies Financial Group in a note issued to investors on Tuesday,London Stock Exchange reports. They presently have a GBX 8.27 target price on the biopharmaceutical company’s stock. Jefferies Financial Group’s target price would indicate a potential downside of 98.66% from the company’s current price.

Separately, Stifel Nicolaus reaffirmed a “buy” rating and set a GBX 950 target price on shares of Oxford Biomedica in a report on Wednesday, March 11th. Six analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of GBX 570.04.

Oxford Biomedica Stock Down 1.9%

Shares of OXB opened at GBX 616 on Tuesday. The company has a debt-to-equity ratio of 116.74, a quick ratio of 1.67 and a current ratio of 2.20. Oxford Biomedica has a one year low of GBX 305.50 and a one year high of GBX 952. The stock has a market capitalization of £744.86 million, a price-to-earnings ratio of -22.88 and a beta of 1.10. The stock has a 50 day moving average price of GBX 604.82 and a 200 day moving average price of GBX 664.32.

Oxford Biomedica (LON:OXB) last issued its quarterly earnings results on Thursday, March 26th. The biopharmaceutical company reported GBX (26.92) EPS for the quarter. Oxford Biomedica had a negative return on equity of 48.56% and a negative net margin of 17.85%. Equities research analysts forecast that Oxford Biomedica will post -31.0799998 earnings per share for the current fiscal year.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.